Substituted tetrahydropyrans as CCR2 modulators
US-9783540-B2 · Oct 10, 2017 · US
Substituted tetrahydropyrans as CCR2 modulators
US10464934B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10464934-B2 |
| Application number | US-201715692811-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 31, 2017 |
| Priority date | May 21, 2015 |
| Publication date | Nov 5, 2019 |
| Grant date | Nov 5, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating a mammal suffering from a disease or disorder selected from the group consisting of diabetic nephropathy, nonalcoholic statohepatitis, and pancreatic cancer, comprising administering to the mammal an effective amount of a compound selected from the group consisting of or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein said compound has the formula or a pharmaceutically acceptable salt thereof. 3. The method of claim 2 , wherein said disease or disorder is diabetic nephropathy. 4. The method of claim 2 , wherein said disease or disorder is nonalcoholic statohepatitis. 5. The method of claim 2 , wherein said disease or disorder is pancreatic cancer. 6. The method of claim 1 , wherein said compound has the formula or a pharmaceutically acceptable salt thereof. 7. The method of claim 6 , wherein said disease or disorder is diabetic nephropathy. 8. The method of claim 6 , wherein said disease or disorder is nonalcoholic statohepatitis. 9. The method of claim 6 , wherein said disease or disorder is pancreatic cancer. 10. The method of claim 1 , wherein said compound has the formula or a pharmaceutically acceptable salt thereof. 11. The method of claim 10 , wherein said disease or disorder is diabetic nephropathy. 12. The method of claim 10 , wherein said disease or disorder is nonalcoholic statohepatitis. 13. The method of claim 10 , wherein said disease or disorder is pancreatic cancer.
Assignees
Inventors
Classifications
having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine · CPC title
having two nitrogen atoms, e.g. dilazep · CPC title
ortho- or peri-condensed with carbocyclic ring systems · CPC title
Drugs for immunological or allergic disorders · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10464934B2 cover?
- Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.
- Who is the assignee on this patent?
- Chemocentryx Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/453. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).